TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00706095
Drug: E7389
Normalized name: Eribulin
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: E7389 Intravenous injection starting dose on Day 1 is 1.1 mg/m\^2 for mild hepatic impairment (Child-Pugh A)
Study: NCT00706095
Drug: E7389
Normalized name: Eribulin
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: E7389 Intravenous injection starting dose on Day 1 is 0.7 mg/m\^2 for moderate hepatic impairment (Child-Pugh B)
Study: NCT00055133
Drug: Micellar Paclitaxel for Injection
Normalized name: Douxo Micellar
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03805503
Drug: Chloroprocaine 1% Injectable Solution
Normalized name: chloroprocaine 1% injectable solution
DrugBank: Procaine (DB00721)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: standard CSE procedure in outpatients for inguinal hernia. The first spinal dose of chloroprocaine 1% to start with is 50mg. This dose has been successfully used for spinal anesthesia in hernia repair outpatients to reach an adequate analgesia. 2,5 microgram of sufentanil will be added for prolongation of the analgesia. The testing interval is 2 mg.~Efficacy of the analgesia will be evaluated:~Successful : sensory block at or above T6 dermatome bilateral at the beginning of surgery without additional analgesia during surgery. Unsuccessful: sensory block under T6 dermatome bilateral and/or VAPS is more than 10 mm at the beginning of surgery what necessitates additional epidurals analgesia.~Patients who indicate an ineffective result will receive a rescue treatment by the administration of 5 ml chloroprocaine 3% epidural every 5 minutes with maximum of 30ml. When CSE fails, general anesthesia will be performed.
Study: NCT01685073
Drug: Zolpidem extended-release
Normalized name: zolpidem Extended Release Oral Tablet
DrugBank: Zolpidem (DB00425)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nightly administration of zolpidem extended-release
Study: NCT00134043
Drug: vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT04525638
Drug: 177Lu-Dotatate
Normalized name: 177Lu-dotatate
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.4 GBq 177Lu-DOTATATE intravenously as a 4-hours infusion
Study: NCT04525638
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 240 mg flat dose of nivolumab intravenously as a 30-minutes infusion
Study: NCT01599130
Drug: Entecavir
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: entecavir 0.5mg per day
Study: NCT01599130
Drug: Peginterferon alfa-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peginterferon alfa-2a 180ug per week
Study: NCT00883623
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Up to 6 cycles of oral L-Mel-Dex, every 28 days Revlimid® 10 mg daily for 21 days, (add on therapy), Melphalan 0.15 mg/kg/day day 1-4, Dexamethasone 20 mg day 1-4
Study: NCT01764230
Drug: triptorelin
Normalized name: triptorelin
DrugBank: Triptorelin (DB06825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Throughout the course of chemotherapy, patients were administered triptorelin (Diphereline SR 3 mg, Ibsen) in the form of i.m. injections, always once a month and simultaneously with the chemotherapy.
Study: NCT01323465
Drug: Sativex and rifampicin
Normalized name: rifampicin and isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of 4 sprays Sativex on Day 1, Rifampicin 2 x 300 mg capsules on Days 2-10, Sativex dose of 4 sprays and rifampicin 2 x 300 mg capsules on Day 11.
Study: NCT01323465
Drug: Sativex and rifampicin
Normalized name: rifampicin and isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifampicin 2 x 300 mg capsules on Days 1-9, Sativex x 4 sprays and rifampicin 2 x 300 mg capsules on Day 10, Single dose of Sativex 4 sprays on Day 18.
Study: NCT01323465
Drug: Sativex and ketoconazole
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of 4 sprays Sativex on Day 1, ketoconazole 2 x 200 mg tablets on Days 2-5, Sativex x 4 sprays and ketoconazole 2 x 200mg on Day 6.
Study: NCT01323465
Drug: Sativex and ketoconazole
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoconazole 2 x 200 mg tablets on Days 1-4, Sativex x 4 sprays and ketoconazole 2 x 200 mg tablets on Day 5, Single dose of 4 sprays Sativex on Day 9.
Study: NCT01323465
Drug: Sativex and omeprazole
Normalized name: omeprazole, amoxicillin and rifabutin
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of 4 sprays of Sativex on Day 1 Omeprazole 2 x 20 mg on Days 2-6. Sativex x 4 sprays and omeprazole 2 x 20 mg on Day 9.
Study: NCT01323465
Drug: Sativex and omeprazole
Normalized name: omeprazole, amoxicillin and rifabutin
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole 2 x 20 mg on Days 1-5, Sativex x 4 sprays and omeprazole 2 x 20 mg on Day 6, Single dose of 4 sprays Sativex on Day 9.
Study: NCT00440466
Drug: epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continue pre-study once weekly dose of epoetin alfa for 36 weeks
Study: NCT00440466
Drug: epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Double the pre-study once weekly dose of epoetin alfa every 2 weeks for 36 wks
Study: NCT00440466
Drug: epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quadruple the pre-study once weekly dose of epoetin alfa every 4 weeks for 36 wk
Study: NCT04341857
Drug: PD-1 Monoclonal Antibody(Sintilimab)
Normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab combined with FLOT regimen,Docetaxel#50mg/m2d1,iv infusion for 1 hour#,Oxaliplatin#80mg/m2d1#iv infusion for 2 hours#,Calcium,leucovate#200mg/m2d1#iv infusion# ,Fluorouracil#2600mg/m2,intravenous drip for 24h# Every 14 days is one cycle# Sintilimab#200mg, d1#iv infusion Every 21 days is one cycle.
Study: NCT00120536
Drug: vildagliptin
Normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Study: NCT03074539
Drug: Riociguat
Normalized name: Riociguat
DrugBank: Riociguat (DB08931)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be treated with Riociguat according to guidelines (2015 ERS/ESC guidelines for the diagnosis and treatment of pulmonary hypertension) and manufacturers recommendation.
Study: NCT02707250
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tap Block performed with Bupivacaine 0,25% 20 ml on the right side and 20 ml on the left side.
Study: NCT00953108
Drug: quetiapine
Normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300 mg per day
Study: NCT00953108
Drug: escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: escitalopram 10 mg per day
Study: NCT01546935
Drug: Oseltamivir
Normalized name: Oseltamivir
DrugBank: Oseltamivir (DB00198)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The dose of Oseltamivir will be 3 mg/kg 12 hourly for 5 days (seasonal influenza and 2009 H1N1) or 10 days (avian influenza) for children whose renal function is ≥ 30 mls/min/1.73m2.
Study: NCT04060342
Drug: nab-paclitaxel and gemcitabine
Normalized name: Paclitaxel
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV infusion
Study: NCT04060342
Drug: pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV infusion
Study: NCT01374139
Drug: Bosutinib
Normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5 clinical 100 mg tablets and 100 mg capsules, 500 mg, single dose, 2x2 crossover under fed condition
Study: NCT01374139
Drug: Bosutinib
Normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4 commercial 100 mg tablets, 400 mg, single dose, 2x2 crossover under fed/fast condition
Study: NCT00209846
Drug: Gaboxadol
Normalized name: Gaboxadol
DrugBank: Gaboxadol (DB06554)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01508897
Drug: liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single dose administered as subcutaneous injection
Study: NCT02707250
Drug: Pethidine
Normalized name: Pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tap Block performed with pethidine 1% 10 ml on the right side and 10 ml on the left side
Study: NCT02707250
Drug: Pethidine Local Infiltration (L.I)
Normalized name: pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local infiltration of port sites (trocar insertion sites) with pethidine 1% 5ml each port (trocar site) ,4 ports total 20 ml pethidine 1%
Study: NCT03419650
Drug: ACTHar
Normalized name: Acthar
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acthar™ 80 units twice a week for 4 weeks followed by 40 units twice a week until week 12.
Study: NCT01905657
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV infusion
Study: NCT00704158
Drug: CR011-vcMMAE
Normalized name: cAC10-vcMMAE
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: administered as an intravenous infusion on Day 1 of a 21 day cycle.
Study: NCT04498741
Drug: EDP-938
Normalized name: INDIGOFERA TINCTORIA LEAF 0.999 in 100 g TOPICAL POWDER [EDP INDIGO]
DrugBank: Indigofera tinctoria leaf (DB14314)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive EDP-938 once daily on Days 10 through 27 (Part 1)
Study: NCT04498741
Drug: EDP-938
Normalized name: INDIGOFERA TINCTORIA LEAF 0.999 in 100 g TOPICAL POWDER [EDP INDIGO]
DrugBank: Indigofera tinctoria leaf (DB14314)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive EDP-938 once daily on Days 5 through 15 (Part 2)
Study: NCT04498741
Drug: EDP-938
Normalized name: INDIGOFERA TINCTORIA LEAF 0.999 in 100 g TOPICAL POWDER [EDP INDIGO]
DrugBank: Indigofera tinctoria leaf (DB14314)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive EDP-938 once daily on Days 5 through 15 (Part 3)
Study: NCT04498741
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive tacrolimus once daily on Day 1 and Day 24
Study: NCT04498741
Drug: Dabigatran
Normalized name: Dabigatran
DrugBank: Dabigatran (DB14726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive dabigatran once daily on Day 1 and Day 13
Study: NCT04498741
Drug: EDP-938
Normalized name: INDIGOFERA TINCTORIA LEAF 0.999 in 100 g TOPICAL POWDER [EDP INDIGO]
DrugBank: Indigofera tinctoria leaf (DB14314)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive EDP-938 once daily on Days 3 through 16 (Part 4)
Study: NCT04498741
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will receive midazolam once daily on Day 1 and Day 16
Study: NCT00411957
Drug: Atazanavir
Normalized name: Atazanavir
DrugBank: Atazanavir (DB01072)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: ATV/r 300/100mg OD vs ATV/r 200/100 mg OD
Study: NCT04032158
Drug: Evobrutinib
Normalized name: Evobrutinib
DrugBank: Evobrutinib (DB15170)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received evobrutinib twice daily (BID).
Study: NCT04032158
Drug: Evobrutinib matched Placebo
DrugBank: Rutin (DB01698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received placebo matched to evobrutinib twice a day.
Study: NCT02496650
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: DEX infusion in doses 0,2-1,4 μg/kg/hr
Study: NCT01261741
Drug: Memantine
Normalized name: Memantine
DrugBank: Memantine (DB01043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each subject will receive memantine 10mg tablets once daily
Study: NCT00004402
Drug: calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01606345
Drug: Valrubicin
Normalized name: Valrubicin
DrugBank: Valrubicin (DB00385)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eligible patients will receive percutaneous valrubicin beginning no sooner than 10 days following nephrostomy placement and within 6 weeks of tumor treatment/resection.
Study: NCT03705507
Drug: Selumetinib
Normalized name: SELUMETINIB
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selumetinib is a small molecule inhibitor of the MEK protein
Study: NCT03705507
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Steroid used for the treatment and management of a number of conditions including cancers and leukaemias.
Study: NCT02176876
Drug: GS-5745
Normalized name: GS-5745
DrugBank: GS-5745 (DB12296)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GS-5745 400 mg administered intravenously
Study: NCT02176876
Drug: Placebo to match GS-5745
Normalized name: GS-5745
DrugBank: GS-5745 (DB12296)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match GS-5745 administered intravenously
Study: NCT00004402
Drug: interferon gamma
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00059787
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT00059787
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00059787
Drug: erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT03421756
Drug: Alemtuzumab
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Alemtuzumab is a non-myeloablative pre-transplant conditioning regimen. Non-myeloablative therapy uses doses of chemotherapy and radiation to weaken (but not destroy) the patients bone marrow and immune system, while still allowing their body will accept the donor's stem cells. Alemtuzumab will be given 7 days prior to stem cell infusion at 0.03 mg/kg IV, 6 days prior to stem cell infusion at 0.1 mg/kg IV, and 5 thru 3 days prior to stem cell infusion at 0.3 mg/kg IV.
Study: NCT03421756
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus will be used for the prevention of graft-verus-host disease and will begin on Day - 1.
Study: NCT01618188
Drug: Faster-acting insulin aspart
Normalized name: diphenhydramine
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A single dose of 0.2 U/kg body weight for subcutaneous (s.c., under the skin) administration.
Study: NCT01618188
Drug: insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A single dose of 0.2 U/kg body weight for subcutaneous (s.c., under the skin) administration.
Study: NCT00292188
Drug: pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: pregabalin
Study: NCT00725478
Drug: Piribedil
Normalized name: piribedil
DrugBank: Piribedil (DB12478)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00822393
Drug: Busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4 x 0.8 mg/kg/d Intravenous Day -4 and -3
Study: NCT00822393
Drug: Treosulfan
Normalized name: TREOSULFAN
DrugBank: Treosulfan (DB11678)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: 10 g/m2/d Intravenous Day -4, -3, -2
Study: NCT02253836
Drug: Tipranavir
Normalized name: Tipranavir
DrugBank: Tipranavir (DB00932)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TPV
Study: NCT02253836
Drug: Ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: RTV
Study: NCT02253836
Drug: Atazanavir
Normalized name: Atazanavir
DrugBank: Atazanavir (DB01072)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: TAZ
Study: NCT04161560
Drug: Cetuximab-IRDye800
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: does of Cetuximab-IRDye800
Study: NCT00795808
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500mg tds for 6 months
Study: NCT00795808
Drug: Metformin + Clomiphene
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500mg tds + Ovulatory dose for 6 months
Study: NCT00795808
Drug: Clomiphene
Normalized name: Clomiphene
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ovulatory dose for 6 months
Study: NCT04449757
Drug: Lactated Ringer's solution
Normalized name: Lactated Ringer's Solution Intravenous Solution
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Method of administration: intravenous infusion; 500-1000ml each time; Speed of infusion: it is decided by the clinicians.
Study: NCT00812422
Drug: Dexibuprofen
Normalized name: Dexibuprofen
DrugBank: Dexibuprofen (DB09213)
Approvals — FDA: no, EMA: no, PMDA: no
Description: one dose of Dexibuprofen 2.5 or 5 mg/kg
Study: NCT00812422
Drug: Dexibuprofen
Normalized name: Dexibuprofen
DrugBank: Dexibuprofen (DB09213)
Approvals — FDA: no, EMA: no, PMDA: no
Description: one dose of Dexibuprofen 3.5 or 7 mg/kg
Study: NCT01426035
Drug: TOPIC MUCOPOLYSACCHARIDE POLYSULFATE CREAM 5MG/G
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: APLIED 4 TIMES/DAY AT LESION
Study: NCT00772135
Drug: sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: capsule of 50 mg , 90 minutes before exercise study
Study: NCT04322149
Drug: AT-1501
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AT-1501 monoclonal antibody targeting CD40L given as an IV infusion
Study: NCT03262727
Drug: BMS-986165
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral administration of specified dose on specified days
Study: NCT03262727
Drug: Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 μg ethinyl estradiol)
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Contraceptive
Study: NCT01936519
Drug: Arm A: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Conversion to Everolimus immunosuppression combined with mycophenolic acid (Myfortic: MPA), and complete discontinuation of Calcineurin inhibitor at 3 months post transplant.
Study: NCT00804141
Drug: N-methylnaltrexone bromide (MOA-728)
Normalized name: Methylnaltrexone Bromide
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MOA-728 will be administered as per the dose and schedule specified in the arm.
Study: NCT01491503
Drug: Levocetirizine
Normalized name: Levocetirizine
DrugBank: Levocetirizine (DB06282)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levocetirizine dihydrochloride 5mg. PO. Single dose.
Study: NCT01491503
Drug: montelukast sodium
Normalized name: Montelukast Sodium
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Montelukast sodium 10mg. PO. Single dose.
Study: NCT01491503
Drug: Montelukast & levocetirizine
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Montelukast sodium 10mg \& levocetirizine dihydrochloride 5mg PO. Single dose.
Study: NCT01764295
Drug: Olmesartan
Normalized name: Olmesartan
DrugBank: Olmesartan (DB00275)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01710254
Drug: Regadenoson MRI
Normalized name: Regadenoson
DrugBank: Regadenoson (DB06213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AF patients will be provided with a regadenoson stress MRI to see if coronary artery disease can be detected with more sensitivity /specificity.
Study: NCT01710254
Drug: Gadobenate dimeglumine
Normalized name: Gadobenate Dimeglumine
DrugBank: Meglumine (DB09415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Resting perfusion with Multihance Gd-BOPTA contrast agent will be performed first, then a regadenoson injection will be given and MR imaging performed with a Gd-BOPTA contrast agent bolus 60-100 seconds later.
Study: NCT02278588
Drug: Rasagiline
Normalized name: Rasagiline
DrugBank: Rasagiline (DB01367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01455337
Drug: pentoxifylline
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400mg tid
Study: NCT01237353
Drug: Rabeprazole
Normalized name: Rabeprazole
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rabeprazole po daily x 5 days
Study: NCT00474851
Drug: Norethindrone acetate + estrogens
Normalized name: Norethindrone Acetate
DrugBank: (2-BROMOETHYL)(2-'FORMYL-4'-AMINOPHENYL) ACETATE (DB07955)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norethindrone acetate 5 mg by mouth daily + Conjugated equine estrogens 0.625 mg by mouth daily
Study: NCT00474851
Drug: norethindrone acetate + placebo
Normalized name: Norethindrone Acetate
DrugBank: (2-BROMOETHYL)(2-'FORMYL-4'-AMINOPHENYL) ACETATE (DB07955)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: norethindrone acetate 5 mg by mouth daily + Placebo capsule 1 pill by mouth daily
Study: NCT01572545
Drug: Denosumab
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Denosumab (injection), 60 mg, administered as a single subcutaneous injection once
Study: NCT01896440
Drug: Ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: There will be two doses investigated in each arm - standard dose (0.15 mg/kg) and high dose (0.3 mg/kg)
Study: NCT01370135
Drug: 0.5mg intraocular Ranibizumab (Lucentis)
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: short- and long-term effects of 0.5mg intraocular Ranibizumab (Lucentis) injections as adjuvant for patients with rubeosis and neovascular glaucoma
Study: NCT02581163
Drug: Ombitasvir/paritaprevir/ritonavir
Normalized name: ombitasvir/paritaprevir/ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Co-formulated tablet